Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors for MASLD in T2DM
NCT06117137Phase 3Completed
- Sponsor
- Sohag University
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin, empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM), sponsored by Sohag University. Started Nov 2023; status: completed.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06117137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117137.